Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 21, 2021

Primary Completion Date

December 8, 2022

Study Completion Date

December 8, 2022

Conditions
Macular Telangiectasia Type 2
Interventions
COMBINATION_PRODUCT

NT-501 CNTF implant

Single implantation of CNTF-secreting NT-501 device into fellow (untreated) eye

Trial Locations (10)

3002

Centre for Eye Research Australia, East Melbourne

6009

Lions Eye Institute, Nedlands

20892

National Eye Institute, Washington D.C.

33136

Bascom Palmer, Miami

44122

Retina Associates of Cleveland, Inc., Beachwood

48105

University of Michigan, Kellogg Eye Center, Ann Arbor

77030

Retina Consultants of Texas, Houston

90095

Jules Stein Eye Institute, Los Angeles

02114

Massachusetts Eye and Ear Infirmary, Retina Service, Boston

Unknown

Save Sight Institute, Sydney

Sponsors
All Listed Sponsors
collaborator

The Lowy Medical Research Institute Limited

OTHER

lead

Neurotech Pharmaceuticals

INDUSTRY

NCT04729972 - Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2 | Biotech Hunter | Biotech Hunter